Vasileios Kourmpetis

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have(More)
  • 1